Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer

Published:2016-12-02 Issue:1 Volume:35 Page:32-35
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Kelley Michael J.¹²³,Jha Gautam⁴,Shoemaker Debra²,Herndon James E.²,Gu Lin²,Barry William T.²⁵,Crawford Jeffrey¹²,Ready Neal¹²

Affiliation:

1. Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA

2. Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA

3. Medical Service, Durham Veterans Affairs Medical Center, Durham, North Carolina, USA

4. Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA

5. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/07357907.2016.1253710

Reference11 articles.

1. Global cancer statistics

2. Vertical Pathway Targeting in Cancer Therapy

3. Development of PI3K inhibitors: lessons learned from early clinical trials

4. Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic effect of cannabidiol with dasatinib on lung cancer by SRC/PI3K/AKT signal pathway;Biomedicine & Pharmacotherapy;2024-04

2. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy;Molecular Biology Reports;2023-03-06

3. Improvement of ACK1-targeted therapy efficacy in lung adenocarcinoma using chloroquine or bafilomycin A1;Molecular Medicine;2023-01-16

4. Genetic Alterations and Deregulation of Hippo Pathway as a Pathogenetic Mechanism in Bone and Soft Tissue Sarcoma;Cancers;2022-12-15

5. Computational Analysis of Drug Resistance Network in Lung Adenocarcinoma;Anti-Cancer Agents in Medicinal Chemistry;2022-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3